- Professor, Global Health
- Professor, Medicine
- Adjunct Professor, Epidemiology
University of Washington
Box 359927
Seattle, WA
United States
Select from the following:
Dr. Celum is Professor of Global Health and Medicine, Adjunct Professor of Epidemiology and co-Director of the International Clinical Research Center in the Department of Global Health at University of Washington. Dr. Celum an infectious disease epidemiologist with a focus on HIV prevention. She has led multi-center HIV prevention efficacy trials, including genital herpes suppression for prevention of HIV acquisition (HPTN 039) and prevention of HIV transmission and disease progression in HIV serodiscordant couples (Partners in Prevention HSV/HIV Transmission Study). Dr. Celum co-led the Partners PrEP Study of tenofovir-based pre-exposure antiretroviral prophylaxis among HIV serodiscordant couples and a demonstration project of ARV-based prevention in serodiscordant couples in Kenya and Uganda (the Partners Demo project). Dr. Celum is leading implementation science research about PrEP implementation for young women in Kenya, South Africa, and Zimbabwe (HPTN 082/HERS, 3Ps, POWER and MTN 034/REACH studies).
- MD (University of California (San Francisco))
- MPH (University of Washington)
- BA (Stanford University)
- Spanish
- Herpes
- HIV/AIDS
- STDs (other than HIV)
- ART Delivery Optimization
- Evaluation of drug level feedback on PrEP adherence among young South African and Zimbabwe women.
- HIV Prevention Trials Network
- HIV self-testing and PrEP to increase testing and prevention uptake among male partners and improve postpartum ART use in PMTCT B+ programs in Uganda
- Microbicide Trials Network – Leadership Operations Center
- POWER: Scaleable, Effective Delivery of Microbicides and PrEP for Young Women in Kenya and South Africa
Celum C, Wald A, Lingappa JR, Magaret AS, Wang RS, Mugo N, et al. Acyclovir and transmission of HIV-1 from persons infected with HIV and HSV-2. N Engl J Med. 2010;362:427-39. PMCID: 2838503.
Celum C, Wald A, Hughes J, Sanchez J, Reid S, Delaney-Moretlwe S, et al. Effect of aciclovir on HIV-1 acquisition in herpes simplex virus 2 seropositive women and men who have sex with men: a randomised, double-blind, placebo-controlled trial. The Lancet. 2008;371:2109-19. PMCID: 2650104.
Baeten JM, Donnell D, Ndase P, Mugo NR, Campbell JD, Wangisi J, et al. Antiretroviral prophylaxis for HIV prevention in heterosexual men and women. N Engl J Med. 2012;367:399-410. PMCID: 3770474.
Celum C, Morrow R, Donnell D, Hong T, Hendrix CW, Thomas K, et al. Daily oral tenofovir and emtricitabine-tenofovir preexposure prophylaxis reduces herpes simplex virus type 2 acquisition among heterosexual HIV-1-uninfected men and women: a subgroup analysis of a randomized trial. Ann Intern Med. 2014; 161:11-9. doi: 10.7326/M13-2471.
Celum C, Morrow R, Donnell D, Hong T, Hendrix CW, Thomas K, et al. Daily oral tenofovir and emtricitabine-tenofovir preexposure prophylaxis reduces herpes simplex virus type 2 acquisition among heterosexual HIV-1-uninfected men and women: a subgroup analysis of a randomized trial. Ann Intern Med. 2014; 161:11-9. doi: 10.7326/M13-2471.